This is a research study for people diagnosed with AML who are not able to receive intensive chemotherapy. The purpose of this study is to see if adding a third drug (magrolimab) to a combination of two drugs (venetoclax and azacitidine) is more effective than using venetoclax and azacitidine.

Do you have AML or MDS and are not eligible to receive intensive chemotherapy? Are you looking for another treatment option? In this study, we want to see if the study drug, SL-172154, works better alone or in combination azacitidine or with azacitidine and venetoclax.

In this study, we want to learn more about the safety and effectiveness of an investigational treatment for relapsed or refractory AML. WU-NK-101 (the study treatment) is an investigational treatment of natural killer cells (NK cells). Natural killer cells are a type of white blood cell that are important for defense against infection and may be able to kill cancer cells.

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.

The purpose of the study is to see how safe and how well the study drug (asciminib) works for patients with CML-CP who have had one prior therapy.

If you or your child has been diagnosed with acute lymphoblastic leukemia (ALL), you or they might be able to take part in a research study. This study aims to understand why there are differences in outcomes in adolescents and young adults treated for ALL.

Do you have relapsed or refractory multiple myeloma? Have you received at least one type of treatment? If so, you may be able to take part in a research study looking at the the safety of giving an investigational medication to patients with multiple myeloma.

A phase III randomized multi-center study designed to compare the efficacy of Crenolanib with that of Midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.

Do you have AML and have received previous chemotherapy or radiation treatment? Are you looking for another treatment option? In this study, we want to see if by adding Pomalidomide a study drug, what dose is the most effective at treating your AML?

Do you have essential thrombocythemia (ET)? If you need to start therapy or your currently therapy is not controlling your ET, you may be able to take part in this research study to find out if a new drug can help normalize your blood count.